The primary benefits of using Semaglutide can include improved blood sugar control, weight loss, and a reduced risk of cardiovascular events such as heart attack and stroke
Understanding where the bottlenecks and enablers lie in the wider GLP-1 ecosystem is essential for investors looking to position themselves for the next wave of growth in weight-loss drugs
Start your intake Current Clinical Evidence on GLP-1 Medications and Lactation Published literature on GLP-1 agonists (semaglutide, tirzepatide, liraglutide) in breastfeeding is extremely limited
Competition will depend on efficacy, dosing, tolerability, supply, price, and indication breadth
Additionally, studies in patients with T2DM are now needed to explore potential clinical benefits [197]